Australia's Dimerix hits nearly 5-year high on US license for its drug

Dimerix

01/05/2025 05:23

** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020

** Stock marks biggest intraday pct gain since October 5, 2023

** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.

** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease

** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg

** Last up 50%, DXB more than doubles YTD

 (Reporting by Kumar Tanishk in Bengaluru)

 ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))